Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Equity Income: 2018-2022

Historic Equity Income for Arcturus Therapeutics Holdings (ARCT) over the last 2 years, with Jun 2022 value amounting to -$131,000.

  • Arcturus Therapeutics Holdings' Equity Income rose 60.06% to -$131,000 in Q2 2022 from the same period last year, while for Jun 2022 it was -$920,000, marking a year-over-year decrease of 240.03%. This contributed to the annual value of -$515,000 for FY2022, which is 200.00% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Equity Income stood at -$131,000 for Q2 2022, which was up 65.89% from -$384,000 recorded in Q1 2022.
  • In the past 5 years, Arcturus Therapeutics Holdings' Equity Income ranged from a high of $1.2 million in Q1 2021 and a low of -$384,000 during Q1 2022.
  • Moreover, its 3-year median value for Equity Income was -$159,000 (2020), whereas its average is -$32,875.
  • Over the last 5 years, Arcturus Therapeutics Holdings' Equity Income had its largest YoY gain of 865.64% in 2021, and its largest YoY loss of 228.00% in 2021.
  • Arcturus Therapeutics Holdings' Equity Income (Quarterly) stood at -$255,000 in 2018, then soared by 81.57% to -$47,000 in 2019, then soared by 43.40% to -$100,000 in 2020, then slumped by 228.00% to -$155,000 in 2021, then skyrocketed by 60.06% to -$131,000 in 2022.
  • Its Equity Income stands at -$131,000 for Q2 2022, versus -$384,000 for Q1 2022 and -$155,000 for Q4 2021.